TARA
Protara Therapeutics, Inc.
There isn't enough reported data to score TARA yet.
TARA Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Unavailable | |
| Unavailable |
TARA's profitability is currently weak. There isn't enough data to rate its revenue, cash flow and balance sheet.
TARA PE Valuation
TARA has no meaningful PE right now: it lost money over the past year.
TARA Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| -- | |
| -- | |
| Limited | |
| Moderate |
Analysts expect TARA's losses to grow, with revenue holding steady.
TARA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.41 | -$0.21 |
| Q2 2026 | -$1.37 | +$0.02 |
| Q1 2026 | -$1.36 | +$0.13 |
| Q4 2025 | -$1.34 | +$0.83 |
| Q3 2025 | -$1.20 | +$1.62 |
| Q2 2025 | -$1.39 | +$1.80 |
| Q1 2025 | -$1.49 | +$2.25 |
| Q4 2024 | -$2.17 | +$1.40 |
TARA is still losing money, but far less than before: $1.41 per share over the past year, against $30.15 at its worst in late 2019.
TARA Quarterly Revenue
TARA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$19.2M | -$6.7M |
| Q4 2025 | -$17M | -$7.7M |
| Q3 2025 | -$12.5M | -$4M |
| Q4 2024 | -$9.3M | -$608K |
| Q3 2024 | -$8.4M | -$1.8M |
| Q4 2023 | -$8.7M | -$3.7M |
| Q3 2023 | -$6.6M | -$1.2M |
| Q2 2023 | -$9.4M | -$4.3M |
TARA has burned cash in almost every quarter: −$61M over the past year, against −$41M the year before.
TARA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3% | +1.8M shares |
| 1 year | +49% | +20.6M shares |
| 3 years | +456% | +51.5M shares |
| 5 years | +460% | +51.6M shares |
| Available history | +12539% | +62.4M shares |
TARA has 63M diluted shares, up 49% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2024 | $76,000 |
| Q4 2023 | — |
| Q3 2023 | $27,000 |
| Q2 2023 | — |
| Q1 2023 | $64,000 |
| Q4 2022 | — |
| Q3 2022 | $18,000 |
| Q2 2022 | — |
TARA Net Leverage
TARA's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
TARA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 30.3 | Neutral |
| Stochastic | 12.5 | Oversold |
TARA's weekly RSI is 30 (neutral) and its Stochastic is 12 (oversold).
TARA PE vs Healthcare Sector
TARA has no meaningful PE right now: it lost money over the past year.
TARA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.58 | 5.4% below |
| 20 week MA | $3.40 | 28% below |
| 50 week MA | $4.59 | 47% below |
| 100 week MA | $4.36 | 44% below |
| 200 week MA | $3.49 | 30% below |
TARA is in a downtrend: it's below all five of its weekly moving averages, and 30% below its 200-week average.
TARA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $14.4 | $23.2 | +61% |
| 2021 | $23.2 | $6.90 | -70% |
| 2022 | $6.90 | $2.77 | -60% |
| 2023 | $2.77 | $1.88 | -32% |
| 2024 | $1.88 | $5.51 | +193% |
| 2025 | $5.51 | $5.55 | +0.7% |
| 2026 YTD | $5.55 | $2.44 | -56% |
TARA's yearly returns have swung widely, from +193% in 2024 to −70% in 2021. It's down 56% so far in 2026.